Fifty years since the first description of an association between HLA and human disease,
HLA molecules have proven to be central to physiology, protective immunity and …

Allogeneic hematopoietic cell transplantation involves consideration of both donor and
recipient characteristics to guide the selection of a suitable graft. Sufficient high-resolution …

CD8+ T cell–dependent killing of cancer cells requires efficient presentation of tumor
antigens by human leukocyte antigen class I (HLA-I) molecules. However, the extent to …

Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly
used to treat hematologic cancers; however, characteristics of the optimal haploidentical …

Recognition of HLA incompatibilities by the immune system represents a major barrier to
allogeneic hematopoietic stem cell transplantation. HLA genotypically identical sibling …

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the most established and
commonly used cellular immunotherapy in cancer care. It is the most potent anti-leukemic …

Over the last 60 years, more than a million patients received hematopoietic cell
transplantation. Having incorporated multiple changes in clinical practices, it remains a …

Accurate prediction of antigen presentation by human leukocyte antigen (HLA) class II
molecules is crucial for rational development of immunotherapies and vaccines targeting …

The highly polymorphic human leukocyte antigen (HLA) locus encodes cell surface proteins
that are critical for immunity. HLA-A expression levels vary in an allele-dependent manner …

Donor factors, in addition to HLA matching status, have been associated with recipient
survival in unrelated donor (URD) hematopoietic cell transplantation (HCT); however, there …